Скачать или смотреть Switching from cetuximab to panitumumab in BRAF V600E mCRC

Annalice Gandini, MD, San Martino University Hospital of Genoa, Genoa, Italy, discusses an international multicenter analysis from the AGEO group assessing outcomes of patients with BRAF V600E mutated metastatic colorectal cancer (mCRC), who discontinued encorafenib-cetuximab due to infusion-related reactions and switched to encorafenib-panitumumab. Panitumumab maintained efficacy with encouraging disease control and was generally well tolerated, with adverse events mostly low grade and no further infusion-related reactions reported. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.